Top

Published in:

01-04-2017 | Novel Aspects in Lupus, 2017

Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls

Authors: Narin-Nard Carmel-Neiderman, David Tanne, Idan Goren, Pnina Rotman-Pikielny, Yair Levy

Published in: Immunologic Research | Issue 2/2017

Abstract

Classical antiphospholipid antibodies (aPLa) are found in 6–25% of blood samples from stroke patients. The frequency of novel aPLa antibodies in blood samples of CVA patients is not known. Enzyme-linked immunosorbent assays (ELISA) were performed on blood samples from 209 CVA patients (170 samples were obtained during the acute phase and 39 samples were from patients with complete carotid stenosis) and compared to 54 healthy controls. Subjects were tested for the presence of the classical aPL antibodies anticardiolipin (aCL) and anti-beta2-glycoprotein (aβ2gI), in addition to antiphosphatidylethanolamine (aPE), anti-phosphatidylserine (aPS), and Annexin V. All antibodies were tested for both IgM and IgG subclasses. Numeric analysis of the antibody titer levels (μ/ml) revealed a significantly higher subclinical titer by two standard deviations of many aPL autoantibodies among CVA patients (Pv < 0.05). However, according to the kit manufacturer’s cutoff value, no positive antibodies were found except a trend toward higher percentage of positive aPS IgG titer in the CVA group compared to controls (6.2 vs. %0; P = 0.077). According to the manufacturer’s cutoff, significantly higher levels of positive antibodies were not found among stroke patients. However, the absolute ELISA values of stroke patients were significantly higher. These results suggest that lower cutoff values than those used for APS diagnosis should be used for risk stratification of CVA among healthy individuals.

Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003;101:157–62.CrossRefPubMed

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed

Sugi T, Matsubayashi H, Inomo A, Dan L, Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res. 2004;30(4):326–32.CrossRefPubMed

Tebo AE, Jaskowski TD, Hill HR, Branch DW. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol. 2008;154(3):332–8.CrossRefPubMedPubMedCentral

Krnic-Barrie S, O’Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997;157(18):2101–8.CrossRefPubMed

Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 1998;7(1):3–6.CrossRefPubMed

Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.CrossRefPubMed

Dobrynina LA, Kalashnikova LA, Pavlova LN. [Ischemic stroke in young age]. Zhurnal Nevrol Psikhiatrii Im SS Korsakova Minist Zdr Meditsinskoĭ Promyshlennosti Ross Fed Vserossiĭskoe Obshchestvo Nevrol Vserossiĭskoe Obshchestvo Psikhiatrov. 2011; 111 (3):4–8.

Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44(6):1466–7.CrossRefPubMed

10.

Dragoni F, Chiarotti F, Rosano G, Simioni P, Tormene D, Mazzucconi MG, et al. Thrombophilic screening in young patients (<40 years) with idiopathic ischemic stroke: a controlled study. Thromb Res. 2011;127(2):85–90.CrossRefPubMed

11.

Ferro JM. Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT). Stroke. 2004;35(3):664–70.CrossRefPubMed

12.

Cantu C, Alonso E, Jara A, Martínez L, Ríos C, Fernández M, de los A, et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke J Cereb Circ. 2004;35(8):1790–1794.

13.

Koniari I, Siminelakis SN, Baikoussis NG, Papadopoulos G, Goudevenos J, Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg. 2010;5:101.CrossRefPubMedPubMedCentral

14.

Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology. 1993; 43(10):2069–73.

15.

Investigators A. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA J Am Med Assoc. 2004;291(5):576–84.CrossRef

16.

Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. 2-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32(8):1701–6.CrossRefPubMed

17.

Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, et al. Antiphospholipid antibodies and stroke in young women. Stroke J Cereb Circ. 2002;33(10):2396–400.CrossRef

18.

Piette JC. Towards improved criteria for the antiphospholipid syndrome. Lupus. 1998;7(Suppl 2):S149–57.CrossRefPubMed

19.

Okuma H, Kitagawa Y, Takagi S. Investigation of antiphosphatidyl-serine antibody and antiphosphatidyl-inositol antibody in ischemic stroke patients. Clin Dev Immunol. 2010;2010:1–4.CrossRef

20.

Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke J Cereb Circ. 1998;29(9):1759–64.CrossRef

21.

Tuhrim S, Rand JH, Wu X, Horowitz DR, Weinberger J, Goldman ME, et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology. 1999;53(7):1523–7.CrossRefPubMed

22.

Okuma H, Kitagawa Y, Kobori S, Sekiyama S, Takagi S. Prevalence rates of antiphospholipid antibodies in ischemic stroke patients. Intern Med Tokyo Jpn. 2006;45(17):1017–8.CrossRef

23.

Okuma H, Kitagawa Y, Ishikawa T, Takagi S. Study of phosphatidylserine-dependent anti-prothrombin antibody in cerebral infarction. Intern Med Tokyo Jpn. 2009;48(16):1351–5.CrossRef

24.

Lee KO, Kim WJ, Na S-J, Heo JH, Lee K-Y. Clinical significance of anti-annexin V antibody in acute cerebral ischemia. J Neurol Sci. 2011;305(1–2):53–6.CrossRefPubMed

25.

Hughes GRV, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62(12):1127.CrossRefPubMedPubMedCentral

26.

Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment: review: antiphospholipid syndrome. J Intern Med. 2011;270(2):110–22.CrossRefPubMed

27.

Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity. Thromb Res. 2007;120(1):127–33.CrossRefPubMed

28.

Yasuda S, Bohgaki M, Atsumi T, Koike T. Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology. 2005;210(10):775–80.CrossRefPubMed

29.

Castillo J, Leira R. Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis Basel Switz. 2001;11(Suppl 1):40–8.

30.

Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci. 1999;162(2):185–8.CrossRefPubMed

31.

Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr K-M, Aarseth J, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005;111(6):360–5.CrossRefPubMed

32.

Orion D, Schwammenthal Y, Reshef T, Schwartz R, Tsabari R, Merzeliak O, et al. Interleukin-6 and soluble intercellular adhesion molecule-1 in acute brain ischaemia. Eur J Neurol Off J Eur Fed Neurol Soc. 2008;15(4):323–8.

Title: Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls
Authors: Narin-Nard Carmel-Neiderman
David Tanne
Idan Goren
Pnina Rotman-Pikielny
Yair Levy
Publication date: 01-04-2017
Publisher: Springer US
Published in: Immunologic Research / Issue 2/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-017-8897-z

At a glance: The STEP trials

Springer Medicine

Classical and additional antiphospholipid antibodies in blood samples of ischemic stroke patients and healthy controls

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Autonomic neuropathy—in its many guises—as the initial manifestation of the antiphospholipid syndrome

Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature

Editorial: Cutting edge in systemic lupus erythematosus

Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study

The microbiome and systemic lupus erythematosus

Dyslipidemia in systemic lupus erythematosus